Bank of New York Mellon Corp - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 94 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$1,754,591
-21.6%
203,313
-5.9%
0.00%
Q2 2023$2,237,184
-1.8%
216,153
+2.9%
0.00%
Q1 2023$2,278,652
-4.0%
210,014
-0.7%
0.00%
-100.0%
Q4 2022$2,374,107
+13.9%
211,596
+3.0%
0.00%0.0%
Q3 2022$2,084,000
+26.5%
205,470
+12.9%
0.00%
Q2 2022$1,648,000
-9.1%
181,915
-4.1%
0.00%
Q1 2022$1,813,000
-12.8%
189,697
+0.7%
0.00%
Q4 2021$2,080,000
+59.3%
188,326
+6.7%
0.00%
Q3 2021$1,306,000
-48.7%
176,421
+0.6%
0.00%
Q2 2021$2,546,000
-38.3%
175,359
-13.3%
0.00%
-100.0%
Q1 2021$4,129,000
+12.8%
202,309
-1.8%
0.00%0.0%
Q4 2020$3,662,000
+17.4%
206,080
-2.3%
0.00%0.0%
Q3 2020$3,119,000
-31.0%
210,975
-2.0%
0.00%0.0%
Q2 2020$4,519,000
-7.3%
215,315
+2.1%
0.00%
-50.0%
Q1 2020$4,875,000
-7.4%
210,968
+3.7%
0.00%
+100.0%
Q4 2019$5,265,000
+37.0%
203,368
+3.1%
0.00%0.0%
Q3 2019$3,843,000
+13.2%
197,271
-5.1%
0.00%0.0%
Q2 2019$3,394,000
-28.4%
207,843
-0.7%
0.00%0.0%
Q1 2019$4,743,000
-10.9%
209,209
+0.5%
0.00%
-50.0%
Q4 2018$5,326,000
-20.7%
208,117
+1.2%
0.00%0.0%
Q3 2018$6,716,000
+43.7%
205,570
-0.3%
0.00%
+100.0%
Q2 2018$4,674,000
-8.2%
206,090
-1.8%
0.00%0.0%
Q1 2018$5,090,000
-13.4%
209,907
-0.4%
0.00%
-50.0%
Q4 2017$5,876,000
-18.4%
210,681
+0.2%
0.00%0.0%
Q3 2017$7,202,000
-13.0%
210,331
+1.3%
0.00%0.0%
Q2 2017$8,274,000
+9.1%
207,707
+0.8%
0.00%0.0%
Q1 2017$7,586,000
+18.5%
206,023
+2.6%
0.00%0.0%
Q4 2016$6,403,000
-20.4%
200,835
-9.5%
0.00%0.0%
Q3 2016$8,039,000
+97.1%
221,844
+23.4%
0.00%
+100.0%
Q2 2016$4,079,000
+51.4%
179,769
+25.4%
0.00%0.0%
Q1 2016$2,695,000
+16.9%
143,372
+2.0%
0.00%0.0%
Q4 2015$2,305,000
+63.0%
140,620
+9.3%
0.00%
Q3 2015$1,414,000
-16.0%
128,616
-0.6%
0.00%
Q2 2015$1,684,000
-18.4%
129,351
+8.7%
0.00%
-100.0%
Q1 2015$2,064,000
+18.7%
118,994
+2.1%
0.00%
Q4 2014$1,739,000
-37.4%
116,508
-3.3%
0.00%
-100.0%
Q3 2014$2,777,000
-63.7%
120,497
-49.8%
0.00%0.0%
Q2 2014$7,660,000240,2500.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2018
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders